PYREXAR HT Hyperthermia products find a distribution with Orientech
SALT LAKE CITY, UT - Pyrexar Medical, was invited to China to speak about the use of hyperthermia in the treatment of cancer. Scientists, researchers, and clinicians met at the Dailan #2 Hospital in the city of Dailan in the Liaoning Province of China to exchange information.
According to the GLOBALCAN study, cancer is the second leading cause of death in the Chinese population and the leading cause of death in urban areas. Lung cancer is the most common cancer, followed by stomach, liver, esophageal, and colorectal cancers.
Hosted by Oreintech, speakers from around the region provided clinical data and usage cases supporting the use of thermal therapies in the treatment of cancer. Representing the United States was Pyrexar Chief Technical Officer Paul Turner. The event also included Dr. Yingying Huang and Dr. Li Ding from Beijing Hospital Oncology Department and Qing Zhang from Beijing Chinese Medicine Hospital (affiliated to The Capital University of Medical Sciences). Topics presented at the conference included: Deep Hyperthermia with Phased Array Methods and Clinical Application; Hyperthermia Combined with Taxol in Malignant Ascites Treatment; Hyperthermia Combined with Chemotherapy in Gastrointestinal Tumors Treatment; and Green Therapy in Oncology-Application of BSD-2000 Annular Phased Array Methods
During the visit, Pyrexar negotiated a new multi-unit purchase agreement for the BSD-2000 Deep Regional Hyperthermia system with Orientech. "Pyrexar is pleased to have Orientech as a distribution partner in China,” says Mark Falkowski, CEO Pyrexar Medical. “Their long commitment to hyperthermia technologies makes them the ideal choice.” In addition, Orientech is also exploring applications where superficial hyperthermia systems, like the BSD-500, may be beneficial to the people of China.
Orientech is a leading manufacturer and distributor of hyperthermia systems in China. With more than 20 years of experience in hyperthermia and oncology, Orientech has developed a highly effective and efficient sales, support, and service network throughout China. In addition to the Oncology Division, Orientech has four other divisions that specialize in Medical Imaging, Orthopedics and Trauma, Wound Management, and Medical Aesthetics, respectively.
Orientech is based in Dalian, China. For more information, please visit www.orientech.net.
ABOUT PYREXAR MEDICAL:
With the acquisition of BSD Medical assets, Pyrexar Medical takes its place as the pioneer and worldwide market leader in the development and manufacture of innovative and highly effective hyperthermia treatment systems with established distribution and support networks in the US, Europe, and Asia. PYREXAR HyperThermia (PYREXAR HT) treatments increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing the toxicity of healthy tissues.
Multi-center clinical trials in the US, Europe, and Asia over the past 30 years document dramatic improvement in survival rates when PYREXAR HT is combined with radiotherapy in the treatment of chest wall recurrences after breast cancer, locally advanced cervical cancer, high-risk soft tissue sarcoma, melanoma, and other malignancies.
Pyrexar Medical is based in Salt Lake City, UT, USA. For more information, please visit our web page at www.pyrexar.com